Programmed Cell Death Protein 1 (PD-1) inhibitors such as Nivolumab and Pembrolizumab in R/M-HNSCC, which were first approved as second-line treatment and have been extended to first-line therapy [2], caused an improved survival with a stable quality of life compared to standard of care. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.